Patents by Inventor Jeffrey Molldrem

Jeffrey Molldrem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
    Patent number: 11192958
    Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: December 7, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jeffrey Molldrem, Anna Sergeeva
  • MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE
    Publication number: 20180371106
    Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Application
    Filed: February 13, 2018
    Publication date: December 27, 2018
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jeffrey MOLLDREM, Anna SERGEEVA
  • Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
    Patent number: 9926380
    Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 27, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jeffrey Molldrem, Anna Sergeeva
  • MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE
    Publication number: 20150191546
    Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 9, 2015
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jeffrey Molldrem, Anna Sergeeva
  • ANTI-CANCER VACCINES
    Publication number: 20110097312
    Abstract: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells.
    Type: Application
    Filed: February 13, 2009
    Publication date: April 28, 2011
    Inventor: Jeffrey Molldrem
  • T-CELL RECEPTORS FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE
    Publication number: 20080064631
    Abstract: The specification describes the sequences for two T-cell receptors—one having a high affinity and one having low affinity for the HLA-A2-restricted peptide PR1. Use of the T-cell receptors and variants thereof in the diagnosis and treatment of cancer and immune-related diseases are also provided.
    Type: Application
    Filed: January 12, 2007
    Publication date: March 13, 2008
    Inventor: Jeffrey Molldrem
  • Vaccines for autoimmune and infectious disease
    Publication number: 20060045884
    Abstract: The present invention provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, translpant rejection or vasculitis in a patient. In particular aspects, there is provided Pr3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from Pr3, which can be used to elicit PR1-specific CTLs. The present invention also provides a HLA-restricted-peptide myeloperoxidases-based methods.
    Type: Application
    Filed: August 26, 2004
    Publication date: March 2, 2006
    Inventor: Jeffrey Molldrem
  • Anti-cancer vaccines
    Publication number: 20060045881
    Abstract: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells.
    Type: Application
    Filed: August 26, 2004
    Publication date: March 2, 2006
    Inventor: Jeffrey Molldrem
  • Anti-cancer vaccines
    Publication number: 20060045883
    Abstract: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.
    Type: Application
    Filed: August 26, 2004
    Publication date: March 2, 2006
    Inventors: Jeffrey Molldrem, A. Barrett